Industry Odisha Bureau, Oct 15: Biocon’s global settlement with Genentech clears patent hurdles for Pebrilzo, its pertuzumab biosimilar. Launch windows open in Europe in 2027 and the US in 2028. Regulatory approvals are still needed.
Biocon has resolved its patent disputes with Genentech over Pebrilzo, a proposed breast cancer biosimilar. The Indian drugmaker disclosed the global settlement and licence agreement in a 14 October filing. The deal gives Biocon agreed windows to enter major international markets.
The agreement resolves all pending disputes between the two companies across several jurisdictions. These include the United States and Canada. It is a settlement and licence, not an acquisition or equity tie-up.
Europe comes first under the agreed timetable. Biocon may launch Pebrilzo in the EU and UK in the first quarter of 2027. A US launch would follow in the third quarter of 2028. Launches in other markets are slated for 2026 to 2028, or earlier in certain circumstances.
These dates flow from the settlement’s terms. They are permitted entry points, not confirmed launch dates. Biocon said launches in every country and region remain subject to regulatory approvals.
That distinction matters. A patent settlement removes legal obstacles to selling a product. It does not show the medicine meets regulators’ standards.
Bodies such as the US Food and Drug Administration still conduct that assessment separately. In Britain, the Medicines and Healthcare products Regulatory Agency plays that role.
Pebrilzo contains pertuzumab, the active substance in Genentech’s reference medicine Perjeta. It is indicated for HER2-positive breast cancer across multiple disease stages. In this form of the disease, tumour cells carry high levels of the HER2 protein. That protein can drive cancer cell growth.
Pertuzumab is a targeted biologic that binds to HER2. Conventional chemotherapy, by contrast, acts more broadly on dividing cells.
A biosimilar is a highly similar version of an approved biologic medicine. Biologics are made from living cells, so exact copies are not possible. Regulators therefore assess biosimilars differently from chemically identical generic drugs.
Patent disputes often decide when biosimilars can reach the market. Litigation can run for years and delay launches unpredictably. Settlements typically replace that uncertainty with agreed entry dates. Biocon’s agreement now offers that clarity across several jurisdictions.
For Biocon, the deal strengthens its oncology biosimilars pipeline in regulated markets. The US, EU and UK are among the world’s most significant pharmaceutical markets. Agreed timelines allow earlier commercial planning for each market.
Biocon has kept the remaining settlement terms confidential. It has not disclosed any payments or royalties involved. That makes the deal’s financial impact difficult to assess.
Biosimilars can widen competition in costly biologic treatment markets. Greater competition may create room for more affordable cancer therapies. Actual prices and patient access, however, depend on approvals and healthcare systems. Commercial arrangements with payers and providers also shape outcomes.
The settlement has removed one major barrier for Pebrilzo. Regulatory clearance remains the next hurdle in each market. Biocon’s return on the deal depends on securing approvals and entering markets successfully.
